Weight-Loss implant could replace weekly shots
NCT ID NCT07430059
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-stage study tests a small implant placed under the skin that releases semaglutide (the drug in Wegovy) over 4 weeks. It involves 20 otherwise healthy overweight or obese adults. The goal is to see if the implant is safe and how it compares to weekly injections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fiber gummies: a tasty new weapon against obesity?
- Can a diabetes drug improve joint replacement outcomes?
- Can a new pill help older adults lose weight without losing strength?
- Can one avocado a day sharpen the aging brain?
- Can a strict diet put type 2 diabetes into remission?
- Can Weight-Loss surgery alter how medications work?